Header Logo

Connection

Katie Kompoliti to Humans

Back to Details
This is a "connection" page, showing publications Katie Kompoliti has written about Humans.
Katie Kompoliti
Connection Strength
0.569
Humans
  1. Sex and Gender Differences in Parkinson's Disease. Neurol Clin. 2023 05; 41(2):371-379.
    View in: PubMed
    Score: 0.046
  2. Multidisciplinary inpatient rehabilitation for Functional Movement Disorders: A prospective study with long term follow up. Parkinsonism Relat Disord. 2021 01; 82:50-55.
    View in: PubMed
    Score: 0.039
  3. Clinical Features of Tourette Syndrome. J Child Neurol. 2020 02; 35(2):166-174.
    View in: PubMed
    Score: 0.036
  4. Mortality and morbidity among hospitalized adult patients with neurological diseases in Cameroon. J Neurol Sci. 2017 Oct 15; 381:165-168.
    View in: PubMed
    Score: 0.031
  5. Functional impairment in Tourette syndrome: parent and child perspectives. Dev Med Child Neurol. 2017 03; 59(3):241.
    View in: PubMed
    Score: 0.029
  6. Immediate vs. delayed treatment of psychogenic movement disorders with short term psychodynamic psychotherapy: randomized clinical trial. Parkinsonism Relat Disord. 2014 Jan; 20(1):60-3.
    View in: PubMed
    Score: 0.024
  7. Impact of placebo assignment in clinical trials of tic disorders. Mov Disord. 2013 Aug; 28(9):1288-92.
    View in: PubMed
    Score: 0.023
  8. Psychogenic movement disorders. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S155-7.
    View in: PubMed
    Score: 0.021
  9. The metabolic landscape of Tourette syndrome: learning to view the elephant as an elephant. Neurology. 2011 Mar 15; 76(11):938-9.
    View in: PubMed
    Score: 0.020
  10. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.019
  11. Complementary and alternative medicine use in Gilles de la Tourette syndrome. Mov Disord. 2009 Oct 15; 24(13):2015-9.
    View in: PubMed
    Score: 0.018
  12. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther. 2008 Jan; 30(1):182-9.
    View in: PubMed
    Score: 0.016
  13. Sialorrhea in Parkinson's disease: a review. Mov Disord. 2007 Dec; 22(16):2306-13.
    View in: PubMed
    Score: 0.016
  14. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.016
  15. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.014
  16. Estrogen and Parkinson's disease. Front Biosci. 2003 May 01; 8:s391-400.
    View in: PubMed
    Score: 0.012
  17. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.011
  18. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
    View in: PubMed
    Score: 0.010
  19. Rating scales and quantitative assessment of tics. Adv Neurol. 2001; 85:31-42.
    View in: PubMed
    Score: 0.010
  20. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.010
  21. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.009
  22. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.009
  23. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.009
  24. Therapeutic approaches. Adv Neurol. 2000; 82:217-21.
    View in: PubMed
    Score: 0.009
  25. Estrogen and movement disorders. Clin Neuropharmacol. 1999 Nov-Dec; 22(6):318-26.
    View in: PubMed
    Score: 0.009
  26. Movement disorders in Kuru. Mov Disord. 1999 Sep; 14(5):800-4.
    View in: PubMed
    Score: 0.009
  27. Neuropharmacology in the elderly. Neurol Clin. 1998 Aug; 16(3):599-610.
    View in: PubMed
    Score: 0.008
  28. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998 Aug; 55(8):1099-102.
    View in: PubMed
    Score: 0.008
  29. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998 Jul; 55(7):957-61.
    View in: PubMed
    Score: 0.008
  30. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov Disord. 1998 May; 13(3):477-80.
    View in: PubMed
    Score: 0.008
  31. Progressive cognitive decline with truncal/limb ataxia and ballistic movements. Mov Disord. 1997 Nov; 12(6):1075-84.
    View in: PubMed
    Score: 0.008
  32. The Association of Poor Academic Performance with Tic Disorders: A Longitudinal, Mainstream School-Based Population Study. Neuroepidemiology. 2017; 48(3-4):155-163.
    View in: PubMed
    Score: 0.008
  33. Tourette syndrome. Clinical rating and quantitative assessment of tics. Neurol Clin. 1997 May; 15(2):239-54.
    View in: PubMed
    Score: 0.008
  34. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May; 71(5):543-52.
    View in: PubMed
    Score: 0.006
  35. Association of tic disorders with poor academic performance in central Spain: a population-based study. J Pediatr. 2013 Jul; 163(1):217-23.e1-3.
    View in: PubMed
    Score: 0.006
  36. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.004
  37. Camptocormia associated with focal myositis in multiple-system atrophy. Mov Disord. 2006 Mar; 21(3):390-4.
    View in: PubMed
    Score: 0.004
  38. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.003
  39. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb; 27(1):30-2.
    View in: PubMed
    Score: 0.003
  40. The importance of educational and psychological factors in Parkinson's disease quality of life. Eur J Neurol. 2002 Nov; 9(6):589-93.
    View in: PubMed
    Score: 0.003
  41. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct; 59(10):1541-50.
    View in: PubMed
    Score: 0.003
  42. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.003
  43. Post-traumatic shoulder 'dystonia': persistent abnormal postures of the shoulder after minor trauma. Neurology. 1998 Oct; 51(4):1205-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.